Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...

Peripheral neuropathy can develop as a complication of rheumatoid arthritis (RA). You may find similar treatments for both, but your doctor is best equipped to determine what medications may work for ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...

Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...

Purpose: The pharmacology, pharmacokinetics, efficacy, safety, drug interactions, dosage and administration, cost, and place in therapy of duloxetine for major depression, pain from diabetic ...

Peripheral Neuropathy in its simplest definition is damage to the peripheral nerves — nerves located outside the brain and spinal cord. It is a relatively common condition that is not isolated to any ...

Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of chemotherapy-induced peripheral neuropathy, has been granted clearance by the FDA allowing the company to initiate a first ...

Peripheral neuropathy pain can be excruciating and life-altering. What many patients don’t realize is that their mysterious nerve pain may actually be connected to an underlying Lyme disease infection ...